Together, we’ll achieve more.

Improving upon existing SureSeq technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (right) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The triple colour design of the Del(5q) Plus Tri-Colour Deletion Probe facilitates the detection of 5q interstitial proximal and distal deletions, in addition to monosomy 5 in AML and MDS analysis. The CytoCell CBFB Breakapart Probe, with its dual colour, dual fusion probe design, detects rearrangements in the 16q22 region and overcomes limitations associated with the proximity of signals on chromosome 16 during interphase FISH for AML detection.

Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (right) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.